Tax Dodger Apple Te...
Health Care: Drugs
Amarin Corporation PLC (AMRN: NASDAQ)
$7.08 0.04 | 0.50%
05/21/13 - 01:26 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -179.18M | -69.13M | -249.59M | -59.32M |
| Operating Gains/Losses | 2.52M | 0.00 | 205.15M | 6.75M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | -21.26M | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | -1.42M | -774.00K | 912.00K | -1.05M |
| (Decrease) Increase In Payables | 25.68M | 5.75M | 1.48M | 0.00 |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | -900.00K |
| (Increase) Decrease In Other Working Capital | -1.06M | -591.00K | 0.00 | 0.00 |
| Other Non-Cash Items | 42.83M | 27.72M | 9.81M | 25.82M |
| Net Cash From Continuing Operations | -122.30M | -39.44M | -33.87M | -28.11M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -122.30M | -39.44M | -33.87M | -28.11M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 700.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -12.69M | -398.00K | -23.00K | -126.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 199.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -14.34M | -2.05M | -23.00K | 773.00K |
| Issuance of Debt | 244.05M | 0.00 | 0.00 | 5.60M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 24.92M | 122.45M | 12.55M | 66.40M |
| Repayment of Long-Term Debt | -20.00K | -2.00K | -12.00K | -2.01M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | -4.19M |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 11.33M | 4.20M | 543.00K | -125.00K |
| Net Cash From Financing Activities | 280.28M | 126.65M | 13.08M | 65.68M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | -317.00K |
| Net Change in Cash & Cash Equivalents | 143.64M | 85.16M | -20.82M | 38.02M |
Portfolios with AMRN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Useralexr685
- ContributorDrugs Facing FDA Approval i...
- ContributorHigh Volume Technicals for ...
- ContributorBreakout Stocks Of The Week...
- UserHassan Portfolio
- Contributor4 Drug Stocks Facing FDA Ap...
- UserLividog
- ContributorStocks Rising On Unusual Vo...
- UserPharma
Latest AMRN Headlines from TheStreet
- Why Keryx is Lagging But Acadia is Zooming (Hint: It's About NCE) 05.21.13 | 10:05 am
- 2013 FDA Drug Approval Calendar 05.21.13 | 07:05 am
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin 05.10.13 | 07:05 am
- Photo Release -- Amarin Reports First Quarter 2013 Financial Results And Provides Update On Operations 05.09.13 | 04:05 pm
- Amarin Trouble Grows As Does Evidence Against Fish Oil's Benefits 05.09.13 | 12:05 am
- Amarin To Report First Quarter 2013 Results And Host Conference Call On May 9, 2013 05.03.13 | 04:05 pm
- Amarin Announces Approval Of Supplemental New Drug Application For BASF As Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier 04.30.13 | 06:04 am
- Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail! 04.26.13 | 08:04 am
- Futures Rise on Key Earnings
04.23.13 | 08:04 am - Amarin Announces FDA Acceptance Of Supplemental New Drug Application (sNDA) For Vascepa(R) For The Treatment Of Patients With High Triglycerides (>200 Mg/dL And <500 Mg/dL) With Mixed Dyslipidemia 04.23.13 | 06:04 am
Press Releases for AMRN
- Amarin To Present At The Deutsche Bank 26th Annual Healthcare Conference - PR Newswire 04.26.11 | 08:04 am
- Amarin's AMR101 Phase 3 ANCHOR Trial Meets All Primary And Secondary Endpoints With Statistically Significant Reductions In Triglycerides At Both 4 Gram And 2 Gram Doses And Statistically Significant Decrease In LDL-C - PR Newswire 04.18.11 | 02:04 am
- Phase 3 MARINE Trial Data To Be Presented In May At The National Lipid Association 2011 Annual Scientific Sessions - PR Newswire 04.05.11 | 08:04 am
- Amarin To Present At The 10th Annual Needham Healthcare Conference - PR Newswire 03.31.11 | 07:03 am
Partner Headlines for AMRN
- Will Amarin’s Positive Test Result Impress These Top Institutional Shareholders? - Wall St. Cheat Sheet 04.08.13 | 01:04 pm
- Will Amarin’s Positive Test Result Impress These Top Institutional Shareholders? - Wall St. Cheat Sheet 04.08.13 | 01:04 pm
- 4 Healthcare Stock Stories for Monday Investment Wellness - Wall St. Cheat Sheet 04.01.13 | 02:04 am
- 4 Healthcare Stock Stories for Monday Investment Wellness - Wall St. Cheat Sheet 04.01.13 | 02:04 am
- Trius Therapeutics: New MSRA Treatment Could Bring Billions In Revenues - Seeking Alpha 03.05.13 | 09:03 am
- Stock Watch Tuesday, 8 January - Seeking Alpha 01.08.13 | 09:01 am
- Stock Watch Wednesday, 2 January - Seeking Alpha 01.02.13 | 08:01 am
- 5 Medical Stock Losers From Last Week With High Short Ratios - Seeking Alpha 12.22.12 | 06:12 am
- Pre-Market Most Active for Dec 7, 2012 : BAC, QQQ, NOK, AMRN, VNTV, AVGO, MEMP, AAPL, FB, SAN, C, FCX - NASDAQ 12.07.12 | 01:12 pm
- After Hours Most Active for Dec 6, 2012 : MMR, BX, QQQ, S, AMRN, EPHC, BAC, EMC, AIG, DISH, LINTA, ORCL - NASDAQ 12.06.12 | 09:12 pm
